Journal ArticleDOI
Revisions in the International System for Staging Lung Cancer
Reads0
Chats0
TLDR
Analysis of a collected database representing all clinical, surgical-pathologic, and follow-up information for 5,319 patients treated for primary lung cancer confirmed the validity of the TNM and stage grouping classification schema.About:
This article is published in Chest.The article was published on 1997-06-01. It has received 4526 citations till now. The article focuses on the topics: Lung cancer staging & Lung cancer.read more
Citations
More filters
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.
Peter Goldstraw,John Crowley,Kari Chansky,Dorothy J. Giroux,Patti A. Groome,Ramón Rami-Porta,Pieter E. Postmus,Valerie W. Rusch,Leslie H. Sobin +8 more
TL;DR: Suggestions include additional cutoffs for tumor size, with tumors >7 cm moving from T2 to T3; reassigning the category given to additional pulmonary nodules in some locations; and reclassifying pleural effusion as an M descriptor.
Journal ArticleDOI
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
Mark G. Kris,Ronald B. Natale,Roy S. Herbst,Thomas J. Lynch,Diane Prager,Chandra P. Belani,Joan H. Schiller,Karen Kelly,Harris Spiridonidis,Alan B. Sandler,Kathy S. Albain,David Cella,Michael K. Wolf,Steven D. Averbuch,Judith Ochs,Andrea C. Kay +15 more
TL;DR: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer
Mark G. Kris,Ronald B. Natale,Roy S. Herbst,Diane Prager,Chandra P. Belani,Joan H. Schiller,Karen Kelly,Harris Spiridonidis,Alan B. Sandler,Kathy S. Albain,David Cella,Michael K. Wolf,Steven D. Averbuch,Judith Ochs,Andrea C. Kay +14 more
TL;DR: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy as mentioned in this paper.
Journal ArticleDOI
Early Lung Cancer Action Project: overall design and findings from baseline screening
Claudia I. Henschke,Dorothy I. McCauley,David F. Yankelevitz,David P. Naidich,Georgeann McGuinness,Olli S. Miettinen,Daniel M. Libby,Mark W. Pasmantier,June Koizumi,Nasser K. Altorki,James P. Smith +10 more
TL;DR: Low-dose CT can greatly improve the likelihood of detection of small non-calcified nodules, and thus of lung cancer at an earlier and potentially more curable stage, although false-positive CT results are common.
Journal ArticleDOI
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Hisayuki Shigematsu,Hisayuki Shigematsu,Li Lin,Takao Takahashi,Masaharu Nomura,Makoto Suzuki,Ignacio I. Wistuba,Kwun M. Fong,Huei Lee,Shinichi Toyooka,Nobuyoshi Shimizu,Takehiko Fujisawa,Ziding Feng,Jack A. Roth,Joachim Herz,John D. Minna,Adi F. Gazdar +16 more
TL;DR: EGFR TK domain mutations are the first molecular change known to occur specifically in never smokers, and can lead to lung cancer pathogenesis.
References
More filters
Journal ArticleDOI
A new international staging system for lung cancer
TL;DR: The International Staging System for Lung Cancer provides for classification of six levels of disease extent in five stage groups that relate to patient management and prognosis and can be readily applied in a broad spectrum of clinical and teaching environments.
Journal ArticleDOI
Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial
TL;DR: Long-term follow-up confirms that patients with stage III NSCLC who receive 5 weeks of chemotherapy with cisplatin and vinblastine before radiation therapy have a 4.1-month increase in median survival.
Journal ArticleDOI
The new International Staging System for Lung Cancer.
TL;DR: The International Staging System for Lung Cancer provides for classification of six levels of disease extent in five stage groups that relate to patient management and prognosis and can be readily applied in a broad spectrum of clinical and teaching environments.
Journal ArticleDOI
The Effect of Surgical Treatment on Survival from Early Lung Cancer: Implications for Screening
TL;DR: Patients with lung cancers detected in stage I by chest x-ray film and treated surgically have a good chance of remaining free of disease for many years and every effort should be made to detect and treat lung cancer early in high-risk populations.
Journal Article
A Prognostic Model of Recurrence and Death in Stage I Non-Small Cell Lung Cancer Utilizing Presentation, Histopathology, and Oncoprotein Expression
TL;DR: Significant univariate predictors of early recurrence and cancer-death were male sex; the presence of symptoms; chest pain; type of cough; hemoptysis; tumor size > 3 cm diameter (T2); poor differentiation; vascular invasion; erbB-2 expression; p53 expression; and a higher KI-67 proliferation index.
Related Papers (5)
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton,Robert B. Livingston,David H. Johnson,James R. Rigas,Michael R. Johnston,Charles Butts,Yvon Cormier,Glenwood D. Goss,Richard Inculet,Eric Vallières,Willard A Fry,Drew Bethune,Joseph Ayoub,Keyue Ding,Lesley Seymour,Barbara Graham,Ming-Sound Tsao,David R. Gandara,Kenneth A. Kesler,Todd L. Demmy,Frances A. Shepherd +20 more